Despite 30% growth, fundamentals remain concerning. Last week, AVITA's stock fell ~20% after reporting preliminary Q4 earnings. The company had been guiding for between $22.3 million and $24.3 ...
(RTTNews) - AVITA Medical, Inc. (RCEL), a regenerative medicine company focused on innovative wound care solutions, announced that the U.S. Food and Drug Administration has approved its premarket ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback